Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.
Anti-Infective Agents
/ therapeutic use
Drug Implants
Eye Infections, Bacterial
/ drug therapy
Fluocinolone Acetonide
/ administration & dosage
Glucocorticoids
/ administration & dosage
Humans
Immunosuppressive Agents
/ therapeutic use
Methotrexate
/ therapeutic use
Panuveitis
/ drug therapy
Rituximab
/ therapeutic use
Sirolimus
/ therapeutic use
Uveitis, Intermediate
/ drug therapy
Uveitis, Posterior
/ drug therapy
Journal
Current opinion in ophthalmology
ISSN: 1531-7021
Titre abrégé: Curr Opin Ophthalmol
Pays: United States
ID NLM: 9011108
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
pubmed:
14
3
2020
medline:
25
4
2020
entrez:
14
3
2020
Statut:
ppublish
Résumé
Local therapeutics play an important role in the management of infectious and noninfectious uveitis (NIU) as well as certain masquerade syndromes. This review highlights the established therapeutics and those under investigation for the management of uveitis. An injectable long-acting fluocinolone acetonide insert was recently approved by the Food and Drug Administration for the treatment of NIU affecting the posterior segment. Intravitreal methotrexate, sirolimus, and anti-vascular endothelial growth factor (VEGF) agents are being evaluated for efficacy in NIU. Intravitreal foscarnet and ganciclovir are important adjuncts in the treatment of viral retinitis as are methotrexate and rituximab for the management of vitreoretinal lymphoma. Local injectable steroids with greater durability are now available for NIU but comparative efficacy to other treatment modalities remains to be determined. Local steroid-sparing immunosuppressive agents are undergoing evaluation for efficacy in NIU as are anti-VEGF agents for uveitic macular edema. Local antivirals may improve outcomes in cases of viral retinitis. Local chemotherapeutics can help induce remission in vitreoretinal lymphoma.
Identifiants
pubmed: 32168001
doi: 10.1097/ICU.0000000000000651
pii: 00055735-202005000-00006
doi:
Substances chimiques
Anti-Infective Agents
0
Drug Implants
0
Glucocorticoids
0
Immunosuppressive Agents
0
Fluocinolone Acetonide
0CD5FD6S2M
Rituximab
4F4X42SYQ6
Sirolimus
W36ZG6FT64
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
174-184Références
Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005; 140:509–516.
Abdulaal MR, Abiad BH, Hamam RN. Uveitis in the aging eye: incidence, patterns, and differential diagnosis. J Ophthalmol 2015; 2015:509456.
Salek SS, Leder HA, Butler NJ, et al. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm 2013; 21:257–263.
Sen HN, Vitale S, Gangaputra SS, et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology 2014; 121:2275–2286.
Sallam A, Taylor SR, Habot-Wilner Z, et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol 2012; 90:e323–e325.
Steeples LR, Anand N, Moraji J, Jones NP. Clinical outcomes of intravitreal preservative-free triamcinolone preparation (Triesence®) for cystoid macular oedema and inflammation in patients with uveitis. Ocul Immunol Inflamm 2018; 26:997–1004.
Ganapathy PS, Lowder CY, Arepalli S, et al. Treatment duration and side effect profile of long-term use of intravitreal preservative-free triamcinolone acetonide in uveitis. Am J Ophthalmol 2018; 194:63–71.
Yang Y, Bailey C, Loewenstein A, Massin P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina 2015; 35:2440–2449.
Muftuoglu IK, Tsai FF, Lin T, Freeman WR. High-dose decanted triamcinolone for treatment-resistant persistent macular edema. Ophthalmic Surg Lasers Imaging Retina 2017; 48:717–726.
Tammewar AM, Cheng L, Kayikcioglu OR, et al. Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections. Br J Ophthalmol 2008; 92:810–813.
Barteselli G, Amini P, Ezon IC, et al. Impact on intraocular pressure after 20-mg decanted triamcinolone acetonide (Kenalog) injection when using prophylactic antiglaucoma therapy. Retina 2015; 35:75–81.
Cheng L, Banker AS, Martin M, et al. Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection. Ophthalmology 2009; 116:1356–1359.
Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129:545–553.
Tomkins-netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology 2014; 121:1649–1654.
Pohlmann D, Vom Brocke GA, Winterhalter S, et al. Dexamethasone inserts in noninfectious uveitis: a single-center experience. Ophthalmology 2018; 125:1088–1099.
Sella R, Oray M, Friling R, et al. Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis. Graefes Arch Clin Exp Ophthalmol 2015; 253:1777–1782.
Tomkins-Netzer O, Talat L, Seguin-Greenstein S, et al. Outcome of treating pediatric uveitis with dexamethasone implants. Am J Ophthalmol 2016; 161:110-5.e1–110-5.e2.
Malclès A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study: incidence and risk factors of ocular hypertension. Retina 2017; 37:1352–1359.
Khurana RN, Bansal AS, Chang LK, et al. Prospective evaluation of a sustained-release dexamethasone intravitreal implant for cystoid macular edema in quiescent uveitis. Retina 2017; 37:1692–1699.
Burkholder BM, Moradi A, Thorne JE, Dunn JP. The dexamethasone intravitreal implant for noninfectious uveitis: practice patterns among uveitis specialists. Ocul Immunol Inflamm 2015; 23:444–453.
Khurana RN, Appa SN, Mccannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology 2014; 121:67–71.
Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011; 118:1916–1926.
Grajewski RS, Boelke AC, Adler W, et al. Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis. Eye 2016; 30:1415–1423.
Tomkins-Netzer O, Lightman S, Drye L, et al. Outcome of treatment of uveitic macular edema: the multicenter uveitis steroid treatment trial 2-year results. Ophthalmology 2015; 122:2351–2359.
Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology 2019; 126:283–295.
Goldstein DA, Do D, Noronha G, et al. Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis. Transl Vis Sci Technol 2016; 5:14.
Yeh S, Kurup SK, Wang RC, et al. Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD). Retina (Philadelphia, Pa) 2019; 39:1880–1888.
Yeh S. Results of the phase III PEACHTREE clinical trial. Vancouver, BC: Presented at the Annual Meeting of the American Society of Retina Specialists; 2018.
Merrill P. Suprachoroidal CLS-TA maintains efficacy outcomes through 48-weeks in uveitic macular edema subjects: results of the MAGNOLIA phase 3 extension study. Park City, UT: Presented at the Winter Symposium of the American Uveitis Society; 2019.
Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113:1020–1027.
Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126:1191–1201.
Kempen JH, Altaweel MM, Holbrook JT, et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010; 149:550.e10–561.e10.
Kempen JH, Altaweel MM, Drye LT, et al. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study. Ophthalmology 2015; 122:1967–1975.
Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis: fifty-four-month results of the multicenter uveitis steroid treatment trial and follow-up study. Ophthalmology 2015; 122:1976–1986.
Kempen JH, Altaweel MM, Holbrook JT, et al. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA 2017; 317:1993–2005.
Jaffe GJ, Lin P, Keenan RT, et al. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology 2016; 123:1940–1948.
Jaffe GJ, Foster CS, Pavesio CE, et al. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology 2019; 126:601–610.
Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 2008; 92:383–388.
Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009; 116:797–801.
Taylor SR, Habot-Wilner Z, Pacheco P, Lightman S. Intravitreal methotrexate in uveitis. Ophthalmology 2012; 119:878–879.
Taylor SR, Banker A, Schlaen A, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 2013; 33:2149–2154.
Khalil HE, El Gendy HA, Youssef HA, et al. The effectiveness of intraocular methotrexate in the treatment of posterior uveitis in Behçet's disease patients compared to retrobulbar steroids injection. J Ophthalmol 2016; 2016:1678495.
Bae JH, Lee SC. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behçet disease. Retina 2012; 32:1395–1402.
Julian K, Langner-Wegscheider BJ, Haas A, De Smet MD. Intravitreal methotrexate in the management of presumed tuberculous serpiginous-like choroiditis. Retina 2013; 33:1943–1948.
Tsui E, Fern CM, Goldberg NR. Treatment of refractory tubercular serpiginous-like choroiditis with intravitreal methotrexate. Retin Cases Brief Rep 2018; [Epub ahead of print].
Mudumba S, Bezwada P, Takanaga H, et al. Tolerability and pharmacokinetics of intravitreal sirolimus. J Ocul Pharmacol Ther 2012; 28:507–514.
Dugel PU, Blumenkranz MS, Haller JA, et al. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology 2012; 119:124–131.
Ibrahim MA, Sepah YJ, Watters A, et al. One-year outcomes of the SAVE study: sirolimus as a therapeutic approach for UVEitis. Transl Vis Sci Technol 2015; 4:4.
Nguyen QD, Sadiq MA, Soliman MK, et al. The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2016; 114:T3.
Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology 2016; 123:2413–2423.
Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther 2012; 28:628–631.
Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol 2012; 154:534.e1–541.e1.
Hamza MM, Macky TA, Sidky MK, et al. Intravitreal infliximab in refractory uveitis in Behçet's disease: a safety and efficacy clinical study. Retina 2016; 36:2399–2408.
Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010; 117:1612–1616.
Hamam RN, Barikian AW, Antonios RS, et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocul Immunol Inflamm 2016; 24:319–326.
Leal I, Rodrigues FB, Sousa DC, et al. Efficacy and safety of intravitreal antitumour necrosis factor drugs in adults with noninfectious uveitis: a systematic review. Acta Ophthalmol 2018; 96:e665–e675.
Agarwal A, Invernizzi A, Singh RB, et al. An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management. J Ophthalmic Inflamm Infect 2018; 8:13.
Levison AL, Baynes KM, Lowder CY, et al. Choroidal neovascularisation on optical coherence tomography angiography in punctate inner choroidopathy and multifocal choroiditis. Br J Ophthalmol 2017; 101:616–622.
Cionni DA, Lewis SA, Petersen MR, et al. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis. Ophthalmology 2012; 119:327–332.
Shantha JG, Ho VY, Patel P, et al. Choroidal neovascularization associated with birdshot chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 2016; 47:450–457.
Schadlu R, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 2008; 145:875–878.
Shah NJ, Shah UN. Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis. Indian J Ophthalmol 2011; 59:318–319.
Yoon DY, Woo SJ. Intravitreal administration of ranibizumab and bevacizumab for choroidal neovascularization secondary to ocular toxocariasis: a case report. Ocul Immunol Inflamm 2018; 26:639–641.
Mabra D, Yeh S, Shantha JG. Ocular manifestations of bartonellosis. Curr Opin Ophthalmol 2018; 29:582–587.
Lee Kim E, Rodger DC, Rao NA. Choroidal neovascularization secondary to tuberculosis: presentation and management. Am J Ophthalmol Case Rep 2017; 5:124–129.
Wu L, Evans T, Saravia M, et al. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol 2009; 53:57–60.
Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina 2009; 29:8–12.
Chang LK, Spaide RF, Brue C, et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008; 126:941–945.
Mavrakanas N, Mendrinos E, Tabatabay C, Pournaras CJ. Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy. Acta Ophthalmol 2010; 88:e54–e55.
Barth T, Zeman F, Helbig H, Gamulescu MA. Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy. Int Ophthalmol 2018; 38:923–931.
Battaglia parodi M, Iacono P, Zucchiatti I, Bandello F. Choroidal neovascularization associated with multiple evanescent white dot syndrome treated with intravitreal ranibizumab. Ocul Immunol Inflamm 2018; 26:608–611.
Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001; 132:794–796.
Van Kooij B, Rothova A, Rijkers GT, De Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 2006; 142:192–194.
Staurenghi G, Lai TY, Mitchell P, et al. Efficacy and safety of ranibizumab 0.5 mg for the treatment of macular edema resulting from uncommon causes: twelve-month findings from PROMETHEUS. Ophthalmology 2018; 125:850–862.
Reddy AK, Cabrera M, Yeh S, et al. Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well controlled uveitis: twelve-month outcomes. Retina 2014; 34:2431–2438.
Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009; 148:303.e2–309.e2.
Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 2011; 31:111–118.
Cordero coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007; 114:1574.e1–1579.e1.
Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 2008; 28:41–45.
Lasave AF, Zeballos DG, El-Haig WM, et al. Short-term results of a single intravitreal bevacizumab (Avastin) injection versus a single intravitreal triamcinolone acetonide (Kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm 2009; 17:423–430.
Flaxel CJ, Yeh S, Lauer AK. Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2013; 111:133–144.
Hafidi M, Janin-Manificat H, Denis P, et al. Acute retinal necrosis: virological features using quantitative polymerase chain reaction, therapeutic management, and clinical outcomes. Am J Ophthalmol 2019; 208:376–386.
Schoenberger SD, Kim SJ, Thorne JE, et al. Diagnosis and treatment of acute retinal necrosis: a report by the American Academy of Ophthalmology. Ophthalmology 2017; 124:382–392.
Wong R, Pavesio CE, Laidlaw DA, et al. Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome. Ophthalmology 2010; 117:556–560.
Boss JD, Rosenberg K, Shah R. Dual intravitreal injections with foscarnet and ganciclovir for ganciclovir-resistant recurrent cytomegalovirus retinitis in a congenitally infected infant. J Pediatr Ophthalmol Strabismus 2016; 53:e58–e60.
Desatnik HR, Foster RE, Lowder CY. Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. Am J Ophthalmol 1996; 122:121–123.
Chavez-de la Paz E, Arevalo JF, Kirsch LS, et al. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis: analysis and prevention. Ophthalmology 1997; 104:539–544.
Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996; 103:1078–1083.
Simonett JM, Igelman A, Taylor SC, et al. Culture-proven endophthalmitis after intravitreal injection: a 10-year analysis. Ophthalmic Surg Lasers Imaging Retina 2019; 50:33–38.
Chen E, Lin MY, Cox J, Brown DM. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina 2011; 31:1525–1533.
Garg SJ, Dollin M, Storey P, et al. Microbial spectrum and outcomes of endophthalmitis after intravitreal injection versus pars plana vitrectomy. Retina 2016; 36:351–359.
McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of antivascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011; 31:654–661.
Simunovic MP, Rush RB, Hunyor AP, Chang AA. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and posttreatment outcomes. Br J Ophthalmol 2012; 96:862–866.
Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 2011; 118:134–141.
Bae JH, Lee SC. Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis. Jpn J Ophthalmol 2015; 59:346–352.
Hariprasad SM, Mieler WF, Lin TK, et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008; 92:871–878.
Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006; 26:935–939.
Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002; 109:1709–1716.
Kvopka M, Lake SR, Smith JR. Intraocular chemotherapy for vitreoretinal lymphoma: a review. Clin Exp Ophthalmol 2019; [Epub ahead of print].
Larkin KL, Saboo US, Comer GM, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol 2014; 98:99–101.
Pulido JS, Johnston PB, Nowakowski GS, et al. The diagnosis and treatment of primary vitreoretinal lymphoma: a review. Int J Retina Vitreous 2018; 4:18.
Venkatesh R, Bavaharan B, Mahendradas P, Yadav NK. Primary vitreoretinal lymphoma: prevalence, impact, and management challenges. Clin Ophthalmol 2019; 13:353–364.